Johns Hopkins University led all U.S. universities in research and development expenditures for the 38th consecutive year in fiscal year 2016, spending $2.431 billion on projects like fighting dengue, finding the functional age of cells, and explaining why the universe is making fewer stars.
Tuesday, April 10, 2018 from 6:00 PM – 8:00 PM
The National Capital SoPE Chapter is moving its meeting to the newly established Inova Personalized Health Accelerator located at 3225 Gallows Road Room C17, Fairfax, Virginia, 22031. We will meet in the Conference Center on the Inova Campus. Our first meeting for the Spring 2018 lineup will be: RED FLAGS in Healthcare/Life Science Due Diligence – What Every Investor and Entrepreneur Should Know!
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces today a $50 million private placement. The Company has entered into definitive securities purchase agreements pursuant to which the Company will issue 15,432,091 shares of its Common Stock with accompanying warrants to purchase 6,172,832 shares of its Common Stock. The purchase price for each share of Common Stock and warrant is $3.24. The warrants will become exercisable 180 days after issuance at a $3.69 per share exercise price, and will expire five years from the date of issuance. On March 19, 2018, the consolidated closing bid price per share of Common Stock was $3.19.
Our country faces an ever-growing number of challenges in the 21st century, but all too often our political dialogue can’t even begin to scratch the surface. While Washington remains mired in its usual partisan fights, entire communities across the country — especially in the Midwest — have been locked out of an economy that has moved away from the manufacturing base that helped build the strongest middle class the world has ever seen.
Friday, May 18, 2018 7:30AM – 3:00PM
Largest Regional Small Business Procurement Conference
MCCC GovConNet Procurement Conference gives over 800 attendees the unique opportunity to gain valuable insights and meet directly with key purchasing agents from a variety of prime contractors and federal, state, and local government agencies.
Wednesday, April 18, 20185:00 PM – 8:00 PM
Please join us on Wednesday, April 18, 2018 for a Healthcare Panel presentation and networking event at the INOVA Personalized Health Conference Center.
Cocktails and hors d’oeuvres will be provided.
American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced receipt of a second immuno-oncology patent on the stimulation of gamma delta T cells for treating solid tumors in epithelial cancers. U.S. Patent No: 9,914,938 dated March 13, 2018 further consolidates AGT’s intellectual property position surrounding its novel gene therapy platform. The patent describes AGT’s unique lentivirus vector approach to modify tumors for potent activation of naturally-occurring T cells in the immune system providing a highly-effective immune response and destruction of tumors.
In the second financing round announced in one day for an immunometabolism startup, Johns Hopkins spinout Dracen Pharmaceuticals just wrapped up a $36 million investment deal from Deerfield.
The $1.3 trillion fiscal 2018 funding package sent to President Trump early Friday includes big boosts for almost all of the major federal agencies, thanks to a broader two-year budget deal increasing spending caps that President Trump signed last month.
New York-based investment firm Deerfield Management is leading a $40 million Series A funding round for Baltimore’s Dracen Pharmaceuticals Inc.
